Primary malignant melanoma of the cervix: Report of 14 cases and review of literature

// Guangwen Yuan 1 , Lingying Wu 1 , Bin Li 1 and Jusheng An 1 1 Department of Gynecologic Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, China Correspondence to: Lingying Wu, email: wulingying@csco.org.cn Keywords: malignant melanoma, treatment, cervix, prognosis Received: January 31, 2017 Accepted: March 27, 2017 Published: April 18, 2017 ABSTRACT Purpose: To investigate the clinical characteristics and prognosis of primary malignant melanoma of the uterine cervix. Results: The median age of the patients was 61.2 years (range, 42-78 years). The median overall survival of the patients at stage I, II and III were 39.2 months, 47.8 months and 9.0 months (P=0.574) and the 2-year overall survival for each stage were 80.0%, 50.0% and 0.0% respectively. Twelve (85.7%) patients developed recurrence and eleven patients (78.6%) died. Ten patients received surgery and four patients were treated with chemotherapy and/or radiotherapy. Immunotherapy was administrated to two patients after surgery. The mean survival time of patients with surgery and without surgery were 47.9 vs.7.75 months (P=0.047). Patients received radical hysterectomy had longer survival than patients underwent total hysterectomy (66.8 months vs 19.5 months, P=0.016). Methods: Clinical data from 14 patients with primary malignant melanoma of the cervix between January 1981 and December 2014 were reviewed. Conclusions: Patients with primary malignant melanoma of the cervix have a poor prognosis. Radical hysterectomy and pelvic lymphnode dissection may offer better prognosis for stage I and II patients.